ArriVent BioPharma Operating Income

ArriVent BioPharma (AVBP) currently reports a operating income of $-140M as of June 2026. That compares with $-82M in the prior-year period — down 68.1% year over year. Use the charts on this page to explore ArriVent BioPharma's operating income history and peer comparisons.

ArriVent BioPharma's operating income decreased from $-82M to $-140M — a 68.1% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ArriVent BioPharma reported $-140M in operating income as of June 2026. That compares with $-82M in the prior-year period — down 68.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-140M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.